Summary The role of glutathione (GSH) and GSH-S-transferase (GST) activity in modulating the cytotoxicity of four platinum drugs and melphalan was evaluated in eight human ovarian carcinoma cell lines. The cell lines were established from solid and ascitic tumours from pretreated and untreated patients, and showed a wide spectrum of sensitivity to several platinum II and in the sensitive (CHI) line after GSH depletion. Moreover the dose modification factor (DMF) for the PtII agents were lower than those for PtIV agents in the three cell lines. The dose modification factor for tetraplatin after BSO treatment was similar to that observed for melphalan in all three cell lines. In the SKOV-3 cell line extending the BSO pretreatment period to 48 h from 24 h marginally reduced the cytotoxicity of cisplatin, whereas the cytotoxicity of the other three drugs remained similar to that observed after 24 h BSO pretreatment. In contrast, extending the BSO treatment to 24 h after drug exposure potentiated the cytotoxicity of cisplatin, CHIP and tetraplatin. The significance of these results in relation to the role of GSH in the mechanism of action of PtII and PtIV drugs is discussed.
Cisplatin, and the markedly less nephrotoxic second generation analogue carboplatin, are exceptionally useful anticancer drugs particularly in the treatment of ovarian and testicular cancers (Calvert et al., 1985; Peckham et al., 1985; Wiltshaw & Carr, 1974) . However, their efficacy is often compromised by the development of resistance after an initial response. Furthermore a number of tumours are unresponsive (intrinsically resistant) to these drugs. Clearly there is a need to develop a new generation of more clinically effective platinum-based drugs and/or to derive methods for modulating the sensitivity of tumours to the currently available drugs. To address these issues we have developed a range of human ovarian carcinoma cell lines and related xenografts, whose reponse to established platinum drugs reflects that seen clinically (Hills et al., 1989; Harrap et al., 1990) . The biochemical mechanisms underlying platinum drug sensitivity/resistance in these models are being characterised. Several mechanisms have been postulated to be involved in platinum drug resistance in tumour cells, including decreased drug accumulation, increased inactivation through interaction with cellular thiols, reduced platinum-DNA adduct formation and enhanced repair of DNA lesions (for review see De Graeff et al., 1988; Eastman & Richon, 1986; Andrews & Howell, 1990) .
Glutathione (GSH), the major intracellular non-protein thiol, plays an important role in a number of cellular functions, including enzyme activity, membrane transport, DNA synthesis and inactivation of xenobiotics and reactive intermediates (Meister & Anderson, 1983) . GSH and GSH-dependent enzymes are known to reduce the cytotoxic activity and hence cause resistance to alkylating agents and several other therapeutic agents (Arrick & Nathan, 1984; Hamilton et al., 1989) . Platinum is known to react avidly with sulphur ligands, hence elevated cellular GSH may reduce the cytotoxicities of platinum drugs. However, the evidence for the involvement of GSH and its dependent enzymes in platinumdrug resistance still remains equivocal. Both elevated and unaltered cellular GSH levels have been reported in murine and human cells, including ovarian carcinoma cells with acquired resistance to cisplatin (Andrews et al., 1985; Hamilton et al., 1985; Lewis et al., 1988; Richon et al., 1987; Teicher et al., 1987) . Moreover, reduction of cellular GSH by D,L-buthionine-S, R-sulfoximine (BSO) pretreatment has had variable effects on cisplatin sensitivity in resistant cells (Andrews et al., 1985 (Andrews et al., , 1988 Hamilton et al., 1985) . The role of GSH in modulating PtIV drug cytotoxicity has not been investigated extensively.
The present report describes our investigations into the role of GSH in modulating the cytotoxicity of platinum drugs in eight human ovarian carcinoma cell lines, established from solid and ascites tumours from pretreated and untreated patients. Levels of GSH and glutathione-S-transferase activity were determined in these cell lines and compared with the cytotoxic activity of several platinum II and IV chemotherapeutic agents: cisplatin [cis-diamminedichloroplatinum(II)], carboplatin [cis-diamminecyclobutane-l,l-dicarboxylatoplatinum(II)], CHIP (iproplatin) [cis-dichloro-bis-iso- propylaminetranshydroxyplatinum(IV)] and tetraplatin [d,l- trans-tetrachloro-1,2-diaminocyclohexaneplatinum (IV) ]. We have also evaluated, in one sensitive and two relatively resistant cell lines, the effect of BSO-mediated depletion of cellular GSH on the cytotoxicity of these four platinum drugs and compared this with the effects on melphalan (L-phenylalanine mustard) cytotoxicity, since the latter has been reported to be 
Cell lines
Eight human ovarian carcinoma cell lines were used in this study. Six (SKOV-3, HX/62, PXN/94, OVCAR-3, CHI and 41M) have been described in detail previously (Hills et al., 1989) . The new lines, LK1 and LK2, were established from ascitic fluid using methods as described previously (Hills et al., 1989) . The patient's pre-biopsy treatment and response were as follows: LKI, carboplatin with partial response and trimelamol with stable disease; LK2, carboplatin with no response and cisplatin with no response.
Drug exposure and cytotoxicity assay Cells were grown in Dulbecco's Modified Eagles Medium (DMEM) plus 10% foetal calf serum, 50 jig ml-' gentamicin, 2.5jLg m1' amphotericin B, 2 mM glutamine, 10 sg ml-' insulin and 0.5 gLg ml-' hydrocortisone. Cells were periodically checked and found to be free of mycoplasma and used in these studies from passage 25 to 50. The sensitivity of each cell line to the four platinum agents (cisplatin, carboplatin, CHIP and tetraplatin) was examined as described previously (Hills et al., 1989) Russo et al. (1986) , by addition of 2.0 ml of cold 0.6% sulphosalicylic acid followed by 10 min incubation at 4°C with occasional shaking. Total GSH in the extract was assayed by the method of Griffiths (1980) . The protein content of the extracted cells was analysed according to Lowry et al. (1951) after solubilisation in 2.0 ml of 1.0 N Effect of BSO exposure on intracellular GSH concentration Preliminary studies were performed to establish the effect of BSO treatment on intracellular GSH content in one sensitive (CHI) and two resistant (SKOV-3 and HX/62) cell lines. Single cells (5 x 105) were plated in T25 flasks and divided into four groups of three flasks. After a 24 h attachment period, the medium was aspirated and replaced with medium containing BSO (2 groups) or vehicle (2 control groups). The BSO concentration ranged from 12.5 jLM to 50 giM, depending on the cell line investigated. One control and one BSO treated group were incubated for 24 h and the remainder were incubated for 48 h. At the end of these periods one flask from each group was used for cell count and the other two were used for GSH determination. Cellular GSH was extracted and analysed as described above. However, GSH was extracted using 1.0 ml of 0.6% sulphosalicylic acid in order to concentrate the extracts. Preliminary experiments had shown that maximum extraction was achieved with this volume. Cell growth and viability 96 h after exposure to BSO at each concentration and time period was also examined in a separate experiment. The BSO concentration and time of exposure which did not alter cell growth and viability were subsequently used to examine the effect of cellular GSH depletion on platinum-drug sensitivity. These values were as follows: 50 tLM BSO, 24 h exposure for the two resistant lines, SKOV-3 and HX/62 and 12.5 giM BSO, 24 h exposure for the sensitive line, CHI.
Effect of cellular GSH depletion on the cytotoxicity of platinum drugs The effect of glutathione depletion on cellular response to platinum drugs was assessed in three cell lines, SKOV-3, HX/62 and CH1 as described above with the following modification. Cells seeded in 96-well microtitre plates were allowed to attach overnight and then incubated in a medium containing an appropriate concentration of BSO or vehicle for a further 24 h. This was followed by a 2 h incubation in medium containing appropriate concentrations of platinum drug and BSO or vehicle. At the end of this period fresh medium was applied and cell survival assessed 96 h later as described above.
Glutathione-S-transferase (GST) assay Following a 24 h attachment period in T25 flasks, cells (3-5 x 106) in log phase growth were washed twice with 20 ml of cold PBS, scraped and harvested using 3.0 ml of PBS. The cell suspension was sonicated (Polytron sonicator, MSE, Fisons Ltd) using 3 x 5 s pulses at 0.75 max power with 20 s cooling period at 4°C between each pulse. The cell sonicate was centrifuged at 11,000 g for 25 min at 4°C and the supernatant analysed for GST activity using 1 mM CDNB as the substrate (Habig et al., 1974) .
Results
Cytotoxicity ofplatinum drugs Cytotoxicity of cisplatin, carboplatin, CHIP and tetraplatin in the eight human ovarian carcinoma cell lines is shown in Figure 1 . The cell lines exhibited a wide range of sensitivity to the four platinum compounds. The HX/62 and SKOV-3 cells lines were generally the most resistant, while the PXN/ 94 cell line showed differential sensitivity to the four platinum agents, being very sensitive to tetraplatin relative to the other three drugs. Figure 2d ). The mechanisms involved in the exquisite sensitivity of the PXN/94 cell line to tetraplatin is currently being investigated.
The ICs values for melphalan also showed a positive correlation (r = 0.77) with cellular GSH content in six of the cell lines. However, statistical significance was not achieved (Table II) . Figure  3a) . Furthermore no growth delay or loss of viabilty were observed 96 h after exposure to 50 SlM BSO up to 48 h. In another resistant cell line, HX/62, treatment with 50 pM BSO for 24 h, which reduced cellular GSH content by 61% also had no effect on cell growth and viability (Figure 3b) . However, exposure to 50 jLM BSO for 48 h did partially reduce the growth rate of these cells. In contrast, in the CHI cell line, which is one of the most sensitive to platinum drugs, exposure to BSO was less well tolerated than in the resistant cell lines. Exposure of CH1 cells to 25 4M BSO for 24 h had an adverse effect on cell viability, although exposure to 12.5ILM BSO for 24 h, which reduced cellular GSH by 81%, was well tolerated (Figure 3c ).
Effect of BSO pretreatment on cytotoxicity ofplatinum-drugs and melphalan Reduction of cellular GSH by 88% in the SKOV-3 cells significantly (P<0.01) potentiated the cytotoxicity of all four Pt drugs. However, the dose modification factor (DMF) for the PtIV drugs, CHIP and tetraplatin was greater than for the PtII drugs, cisplatin and carboplatin (Table III) . In the HX/62 cell line a 61% reduction in its GSH content did not potentiate the cytotoxicity of PtII drugs, whereas the sensitivity to PtIV drugs was significantly enhanced (Table III) . In both SKOV-3 and HX/62 cell lines the DMF for tetra- Ufi-" platin was similar to that observed for melphalan. An 81% depletion of intracellular GSH in the sensitive CHI cells caused a significant potentiation of PtII drug cytotoxicity. Moreover, the DMFs for these drugs were greater than those observed in the resistant lines (Table III) . Tetraplatin and melphalan cytotoxicity in the CHl cells was enhanced to a similar extent as that seen in the resistant cells after GSH depletion (Table III) . In preliminary experiments with SKOV-3 cells we observed that extending the BSO pretreatment period from 24 h to 48 h before exposure to the drugs marginally reduced the DMF for cisplatin from 1.25-1.33 (range, n = 2) to 0.72-0.92 (range, n = 2), whereas the DMF for carboplatin, CHIP and tetraplatin remained similar in the two groups. In addition, exposure of the SKOV-3 cells to 50 tLM BSO for 24 h prior to and following drug treatment increased the DMF for cisplatin, CHIP and tetraplatin relative to that observed after 24 h BSO pretreatment only (Table IV) . In contrast, the DMF for carboplatin in these two treatment groups was similar.
Intracellular GST concentrations The GST activity in the eight cell lines, measured using 1-chloro-2, 4-dinitrobenzene as the substrate, are shown in Table I . No correlation was observed between GST activity and IC50 values for any of the four platinum drugs examined.
Discussion
In this study we have measured GSH levels in eight human ovarian carcinoma cell lines established from patients who were either untreated or pretreated with platinum and nonplatinum-containing regimens. This panel of lines had a range of sensitivity to platinum drugs similar to that observed in the clinic (Hills et al., 1989) ; with the SKOV-3 and HX/62 cells lines being the most refractory (relatively resistant), and the CHI line being one of the most sensitive. Cellular GSH was determined in cells grown under conditions reflecting those used for drug cytotoxicity assay, because GSH and GSH-dependent enzyme levels vary with time after plating in both murine and human cells (Batist et al., 1986; Post et al., 1983) . Indeed, in agreement with these reports, our own data showed that GSH levels per 106 cells were higher at 24 h than at 48 h after plating. The GSH concentrations in the eight ovarian cell lines showed a strong inverse correlation with sensitivity to both PtII and PtIV group drugs. As far as we are aware this is the first time such a correlation has been observed in a group of human ovarian carcinoma cells with such a wide (approximately 100-fold) range of sensitivity to platinum drugs (Hills et al., 1989) . Recently Hosking et al. (1990) have reported a correlation between cisplatin sensitivity in various cell types and their GSH content. Elevated GSH levels in human cells with acquired resistance to cisplatin have also been reported (Hamilton et al., 1985; Lewis et al., 1988; Teicher et al., 1987) . In one study, Lewis et al. (1988) found that, relative to a sensitive ovarian cell line (PEOI), GSH and GSHdependent enzymes were higher in a resistant (PE04) line established from the same patient after relapse on cisplatincontaining therapy.
To establish whether the elevated GSH levels played a role in the mechanism of resistance to platinum drugs we examined the effect of BSO-mediated GSH depletion on the cytotoxicity of these drugs in one sensitive (CHI) and two relatively resistant (SKOV-3, HX/62) cell lines. The cell lines were found to be differentially sensitive to BSO exposure, with the most sensitive being the CHI cell line, followed by HX/62 and then SKOV-3; hence the platinum resistant cells were more tolerant to BSO than the platinum sensitive cells. Depletion of cellular GSH had a differential effect on the cytotoxicity of PtII vs PtIV complexes in these three cell lines. The cytotoxicity of PtIV drugs was enhanced significantly (P<0.05) in all three cell lines whereas the cytotoxicity of the PtII drugs was only significantly enhanced in one n. r- & Smith, 1988) . However, Andrews et al. (1985) showed no alteration in sensitivity to CHIP or PtII drugs after GSH depletion in human ovarian cell lines with acquired resistance to cisplatin. These authors subsequently reported (Andrews et al., 1988) that cisplatin resistance in these cells could be partially reversed if GSH depletion was maintained after drug treatment by prolonging the exposure to BSO. Maintenance of BSO exposure during cisplatin treatment also increased drug cytotoxicity in both sensitive and resistant A2780 ovarian carcinoma cell lines (Hamilton et al., 1985) . Our results also showed that, in the relatively resistant SKOV-3 cell line, maintenance of GSH depletion 24 h after drug treatment increased the DMF for cisplatin, CHIP and tetraplatin relative to that observed when cells were pretreated with BSO for 24 h only. This increase may be due to inhibition of DNA repair as well as reduced inactivation of active species as a result of GSH depletion .
The fact that the DMF for PtIV drugs were greater than those for PtII drugs in the relatively resistant cells suggests that GSH may play a more significant role in the mechanism of resistance to PtIV than PtII drugs. However, it is possible that BSO may have interfered with PtII drug action, particularly that of cisplatin, in the two resistant cell lines either directly or indirectly through a mechanism which counteracts the beneficial effects of GSH depletion. Evidence to support this comes from the fact that the DMFs for cisplatin after 24 h BSO exposure in the resistant cells were marginally higher than those observed after 48 h BSO treatment. In addition, cisplatin induced nephrotoxicity has been shown to be augmented by concomitant administration of BSO (Mayer et al., 1987) . The differential sensitisation of the resistant ovarian cells to PtII and PtIV drugs after BSO pretreatment may be due to the differences in the rate at which GST catalyses the reaction of these complexes with GSH. The relationship between GST activity and platinum drug action is unclear and both increased and unaltered activity have been reported in cells with acquired resistance to cisplatin (Hamilton et al., 1985; Lewis et al., 1988; Wang et al., 1989 ).
Our own data showed no correlation between total GST activity and sensitivity to the four platinum drugs. However, it is possible that a specific isoenzyme may mediate a differential response, and GST isoenzyme profiles are currently being investigated in these cell lines. The fact that the DMFs for tetraplatin and the PtII drugs are different after GSH depletion is intriguing because the complex entering the ovarian cells after exposure to tetraplatin is probably 1,2-diaminocyclohexanedichloroplatinum (II), since tetraplatin is rapidly reduced to this complex (t1, 5-15 min) in RPMI tissue culture medium and plasma (Gibbons et al., 1989) . Our own data (unpublished) have also shown a very rapid reduction of tetraplatin by the ovarian cell culture medium. Moreover, the enhancement of PtIV drug cytotoxicity after GSH depletion is interesting since it is widely believed that these drugs are activated by reduction to PtII complexes and that this process is partially mediated by intracellular GSH (Cleare, 1977; Eastman, 1987) . On this basis GSH depletion should have antagonised PtIV drug cytotoxicity.
Our data confirm that melphalan cytotoxicity is greatly enhanced by GSH depletion in both sensitive and resistant ovarian carcinoma cell lines (Andrews et al., 1985; Green et al., 1984; Hamilton et al., 1985) . Moreover the DMF values observed for tetraplatin were similar to those observed for melphalan in the three cell lines examined. If the enhanced cytotoxicity of tetraplatin and CHIP after GSH depeletion represents a typical response of PtIV complexes then this could be of significance in future platinum drug development.
In summary, intracellular GSH but not GST levels showed a strong inverse correlation with sensitivity to PtII and PtIV drugs in eight human ovarian carcinoma cell lines. However, modulation of platinum drug cytotoxicity in response to BSO pretreatment suggests that GSH may play a more significant role in the mechanism of resistance to PtIV than PtII drugs. The mechanisms involved in this differential response are unknown and need to be investigated further along with the intracellular metabolism of these complexes in order to evaluate the exact role of GSH and GSH-dependent enzymes in modulating platinum drug action.
